ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) Director Jeanne Thoma sold 1,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the transaction, the director owned 26,762 shares of the company’s stock, valued at approximately $1,914,285.86. This trade represents a 3.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Trading Up 0.3%
ANIP stock opened at $70.40 on Tuesday. ANI Pharmaceuticals, Inc. has a 52-week low of $69.58 and a 52-week high of $99.39. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1.62 billion, a P/E ratio of 15.17 and a beta of 0.45. The company’s 50-day simple moving average is $76.97 and its 200-day simple moving average is $78.17.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Research Report on ANIP
Hedge Funds Weigh In On ANI Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in ANIP. Tidal Investments LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth about $248,000. WINTON GROUP Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth about $4,558,000. Corient Private Wealth LP grew its stake in ANI Pharmaceuticals by 95.2% during the 2nd quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock valued at $1,995,000 after acquiring an additional 11,754 shares in the last quarter. Amundi grew its stake in ANI Pharmaceuticals by 595.5% during the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock valued at $2,632,000 after acquiring an additional 27,222 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $1,449,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
